GLUE logo

MONTE ROSA THERAPEUTICS INC

GLUENASDAQ
🏆 #2485 by market capEarnings Nov 4US Equity
$718.61▲ $34.78 (+4.84%)
Simulated price
🔔
Track GLUE
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$987M
Small Cap
📈Revenue Growth (YoY)
+63.5%
High Growth
📊Gross Margin
92.9%
High
💵FCF Margin
-248.3%
Thin
⚖️P/S Ratio
34.4x
Expensive
Otter Score
88
Very Good
No chart data available for GLUE.

Trading Snapshot

Day Range
$714.22 – $723.97
52-Week Range
$7.09 – $25.77
Volume
$2.95B
Avg Volume
$3.14B
Shares Outstanding
84.5M
Next Earnings
Dec 10, 2026

Fundamentals Snapshot

Annual Revenue
$124M
Last Q Revenue
$9M
P/E Ratio
-5.4
P/S Ratio
34.4x
EPS (TTM)
$-1.89
Dividend Yield
0.00%
Dilution (1yr)
+6.7%

Why Investors Own GLUE

  • ✓High-growth profile — revenue up +37.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 78% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GLUE logo

MONTE ROSA THERAPEUTICS INC

GLUE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$124M▲ +63.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.2%▲ +4.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$54M▼ −33.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$27M▼ −172.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
65.5M▲ +6.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$91M▼ −$91M YoY
StockOtter · stockotter.space

About MONTE ROSA THERAPEUTICS INC

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Very Good
88/100

Analyst Price Target

ⓘ
Average Target
$852.37
▲ +18.6% Upside
High Target$992.89
Low Target$799.94
Based on 22 analysts

Latest News & Updates

🚀
Barron’s·2h ago

MONTE ROSA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift GLUE price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

MONTE ROSA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.